Carrimycin - Shenyang Tonglian Group
Alternative Names: Biotechmycin; Biotechspiramycin; LevocarrimycinLatest Information Update: 18 Aug 2023
At a glance
- Originator Shenyang Tonglian Group
- Class Antibacterials; Antineoplastics; Antivirals; Macrolides
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections
- No development reported COVID-19 pneumonia; Head and neck cancer; Sepsis
Most Recent Events
- 18 Aug 2023 Beijing Friendship Hospital plans a clinical trial in Haemophagocytic lymphohistiocytosis (Treatment-experienced) in China (PO, Tablets) in August 2023 (NCT05988177)
- 28 May 2023 No recent reports of development identified for phase-0 development in Sepsis in China (PO, Tablet)
- 28 Mar 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-19 pneumonia in China